Novabay Pharmaceuticals Stock Price To Earnings To Growth

NBY Stock

USD 0.60 0.01 1.69%

NovaBay Pharmaceuticals fundamentals help investors to digest information that contributes to NovaBay Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of NovaBay Stock. The fundamental analysis module provides a way to measure NovaBay Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NovaBay Pharmaceuticals stock.

Total Liab Other Stockholder Equity

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

NovaBay Pharmaceuticals Company Price To Earnings To Growth Analysis

NovaBay Pharmaceuticals' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.

PEG Ratio

PE Ratio

EPS Growth

More About Price To Earnings To Growth | All Equity Analysis

NovaBay Price To Earnings To Growth Driver Correlations

Understanding the fundamental principles of building solid financial models for NovaBay Pharmaceuticals is extremely important. It helps to project a fair market value of NovaBay Stock properly, considering its historical fundamentals such as Price To Earnings To Growth. Since NovaBay Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of NovaBay Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of NovaBay Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Total Liab	Net Debt	Retained Earnings	Accounts Payable	Total Current Assets	Common Stock	Property Plant Equipment	Current Deferred Revenue	Short Term Debt	Net Receivables	Net Tangible Assets	Capital Surpluse	Deferred Long Term Liab	Short Long Term Debt	Cash And Equivalents	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.83	0.45	-0.61	-0.25	-0.16	0.87	0.59	0.3	-0.11	0.0	-0.28	0.17	0.24	-0.17	-0.4	0.09	0.45	0.47	0.25
Total Stockholder Equity	0.83		-0.11	-0.76	-0.04	-0.4	0.88	0.62	0.33	0.06	-0.18	-0.12	0.58	0.1	-0.34	-0.42	0.19	0.5	0.51	0.23
Total Liab	0.45	-0.11		0.06	-0.34	0.37	0.16	0.1	-0.06	-0.29	0.24	-0.29	-0.6	0.25	0.24	-0.02	-0.14	0.04	0.06	0.04
Net Debt	-0.61	-0.76	0.06		-0.39	0.22	-0.86	-0.49	0.19	0.16	0.17	0.21	-0.69	0.3	0.22	0.15	-0.55	-0.29	-0.4	0.35
Retained Earnings	-0.25	-0.04	-0.34	-0.39		-0.06	0.06	-0.08	-0.42	0.05	-0.13	0.05	0.51	-0.94	-0.08	0.31	0.44	-0.42	-0.27	-0.65
Accounts Payable	-0.16	-0.4	0.37	0.22	-0.06		-0.29	0.14	0.09	-0.65	0.23	-0.48	-0.69	0.0	0.05	-0.16	0.12	-0.17	-0.13	0.11
Total Current Assets	0.87	0.88	0.16	-0.86	0.06	-0.29		0.51	0.15	-0.1	-0.02	-0.28	0.51	-0.04	-0.17	-0.17	0.27	0.28	0.32	-0.04
Common Stock	0.59	0.62	0.1	-0.49	-0.08	0.14	0.51		0.19	-0.28	0.05	-0.28	0.06	0.16	-0.61	-0.39	0.12	0.53	0.54	0.37
Property Plant Equipment	0.3	0.33	-0.06	0.19	-0.42	0.09	0.15	0.19		-0.08	0.26	-0.36	-0.19	0.35	-0.08	-0.42	-0.14	-0.02	-0.1	0.79
Current Deferred Revenue	-0.11	0.06	-0.29	0.16	0.05	-0.65	-0.1	-0.28	-0.08		-0.69	0.88	0.28	0.01	0.13	0.39	-0.56	-0.06	-0.06	0.05
Short Term Debt	0.0	-0.18	0.24	0.17	-0.13	0.23	-0.02	0.05	0.26	-0.69		-0.74	-0.28	0.01	-0.17	-0.04	0.19	-0.27	-0.35	0.08
Net Receivables	-0.28	-0.12	-0.29	0.21	0.05	-0.48	-0.28	-0.28	-0.36	0.88	-0.74		0.15	0.06	0.08	0.38	-0.53	0.06	0.05	-0.06
Net Tangible Assets	0.17	0.58	-0.6	-0.69	0.51	-0.69	0.51	0.06	-0.19	0.28	-0.28	0.15		-0.41	-0.13	0.01	0.4	0.14	0.2	-0.39
Capital Surpluse	0.24	0.1	0.25	0.3	-0.94	0.0	-0.04	0.16	0.35	0.01	0.01	0.06	-0.41		0.02	-0.35	-0.43	0.52	0.39	0.67
Deferred Long Term Liab	-0.17	-0.34	0.24	0.22	-0.08	0.05	-0.17	-0.61	-0.08	0.13	-0.17	0.08	-0.13	0.02		0.18	0.12	-0.14	-0.13	-0.07
Short Long Term Debt	-0.4	-0.42	-0.02	0.15	0.31	-0.16	-0.17	-0.39	-0.42	0.39	-0.04	0.38	0.01	-0.35	0.18		-0.39	-0.66	-0.67	-0.43
Cash And Equivalents	0.09	0.19	-0.14	-0.55	0.44	0.12	0.27	0.12	-0.14	-0.56	0.19	-0.53	0.4	-0.43	0.12	-0.39		0.11	0.22	-0.34
Net Invested Capital	0.45	0.5	0.04	-0.29	-0.42	-0.17	0.28	0.53	-0.02	-0.06	-0.27	0.06	0.14	0.52	-0.14	-0.66	0.11		0.98	0.3
Net Working Capital	0.47	0.51	0.06	-0.4	-0.27	-0.13	0.32	0.54	-0.1	-0.06	-0.35	0.05	0.2	0.39	-0.13	-0.67	0.22	0.98		0.19
Capital Stock	0.25	0.23	0.04	0.35	-0.65	0.11	-0.04	0.37	0.79	0.05	0.08	-0.06	-0.39	0.67	-0.07	-0.43	-0.34	0.3	0.19

Click cells to compare fundamentals

Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.

Competition

Predict NovaBay Pharmaceuticals

NovaBay Price Earnings To Growth Ratio

Price Earnings To Growth Ratio

0.001541

At this time, NovaBay Pharmaceuticals' Price Earnings To Growth Ratio is fairly stable compared to the past year.

Based on the latest financial disclosure, NovaBay Pharmaceuticals has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Pharmaceuticals sector and 100.0% lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is 100.0% higher than that of the company.

Did you try this?

Run Bonds Directory Now

Bonds Directory

Find actively traded corporate debentures issued by US companies

All Next

Launch Module

NovaBay Fundamentals

	Return On Equity	-2.64
	Return On Asset	-0.39
	Profit Margin	(0.77) %
	Operating Margin	(0.43) %
	Current Valuation	3.44 M
	Shares Outstanding	4.89 M
	Shares Owned By Insiders	0.02 %
	Shares Owned By Institutions	2.58 %
	Number Of Shares Shorted	187.04 K
	Price To Earning	(5.43) X
	Price To Book	2.76 X
	Price To Sales	0.23 X
	Revenue	14.73 M
	Gross Profit	5.64 M
	EBITDA	(4.8 M)
	Net Income	(9.64 M)
	Cash And Equivalents	5.36 M
	Cash Per Share	0.07 X
	Total Debt	2.74 M
	Debt To Equity	0.14 %
	Current Ratio	2.59 X
	Book Value Per Share	0.22 X
	Cash Flow From Operations	(4.13 M)
	Short Ratio	0.19 X
	Earnings Per Share	(74.61) X
	Target Price	3.73
	Number Of Employees	24
	Beta	0.73
	Market Capitalization	2.95 M
	Total Asset	9.03 M
	Retained Earnings	(174.85 M)
	Working Capital	2.88 M
	Current Asset	4.53 M
	Current Liabilities	4.63 M
	Net Asset	9.03 M

About NovaBay Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze NovaBay Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NovaBay Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NovaBay Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for NovaBay Stock Analysis

When running NovaBay Pharmaceuticals' price analysis, check to measure NovaBay Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NovaBay Pharmaceuticals is operating at the current time. Most of NovaBay Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NovaBay Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NovaBay Pharmaceuticals' price. Additionally, you may evaluate how the addition of NovaBay Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC